NASDAQ · RLAY
Relay Therapeutics, Inc.
$19.47-$0.22 (-1.12%)
Relay Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.46% below the high.
Loading market information…
NASDAQ · FTH · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Faeth Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Faeth Therapeutics, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.72. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Faeth Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 28, 2025 |
| -$5.400.0% vs estimate |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$5.80+6.45% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $58.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$19.47-$0.22 (-1.12%)
Relay Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.46% below the high.
$22.53+$0.30 (+1.35%)
Tango Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.49% below the high.
$4.77+$0.18 (+3.92%)
Nuvation Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.08% below the high.
$17.83-$0.22 (-1.22%)
Janux Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.55% below the high.
$10.56-$0.16 (-1.49%)
Kura Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.03% below the high.
$9.66-$0.18 (-1.78%)
Verastem, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.72% below the high.
$10.54-$0.08 (-0.75%)
Puma Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.35% below the high.
$4.10-$0.04 (-0.97%)
Prelude Therapeutics Incorporated’s quoted price sits in the upper half of its reported 52-week range, 39.97% below the high.
